Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5867 Articles

Chris Lange | Oct 4, 2018 at 11:40 AM EDT

Why Arrowhead Pharma’s New Agreement Is a Big Deal

Arrowhead Pharmaceuticals shares stumbled on Thursday after it announced a license and collaboration agreement with Janssen Pharmaceutica, a subsidiary of…

Chris Lange | Oct 2, 2018 at 12:10 PM EDT

Clovis Wins Big With FDA Update

Clovis Oncology shares jumped on Tuesday after the U.S. Food and Drug Administration (FDA) gave a critical update.

Chris Lange | Oct 1, 2018 at 11:50 AM EDT

Pfizer Announces Big Changes at the Top

Pfizer shares hit multiyear highs and nearly an all-time in Monday’s session after the pharma giant announced a succession plan…

Chris Lange | Oct 1, 2018 at 10:25 AM EDT

Why Akorn Shares Were Halved

Akorn shares were crushed early on Monday after a Delaware judge ruled that German health care group Fresenius could walk…

Chris Lange | Sep 29, 2018 at 8:15 AM EDT

Major Biopharma Catalysts on October’s FDA Calendar

Here is a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month…

Chris Lange | Sep 28, 2018 at 10:55 AM EDT

Equillium Prepares for IPO

Biotechnology company Equillium has amended its filing with the SEC regarding its initial public offering.

Jon C. Ogg | Sep 27, 2018 at 1:10 PM EDT

Why Aldeyra Could Have Another 100% Upside, or More

Two research firms have called for major upside ahead Aldeyra Therapeutics, even after the big pop in the stock on…

Chris Lange | Sep 27, 2018 at 11:10 AM EDT

US DEA Updates Schedule of Cannabidiol for GW Pharmaceuticals

GW Pharmaceuticals shares made a solid gain on Thursday after it received a critical update from the DEA.

Chris Lange | Sep 27, 2018 at 10:15 AM EDT

Protagonist Therapeutics Wins FDA Fast Track

Protagonist Therapeutics shares made a solid gain on Thursday after the company announced a key update from the FDA.

Chris Lange | Sep 27, 2018 at 9:45 AM EDT

Why Geron Is Getting Crushed

Geron shares were absolutely crushed on Thursday morning after it was announced that Janssen Biotech has terminated the 2014 collaboration…

Lee Jackson | Sep 27, 2018 at 8:35 AM EDT

Merrill Lynch Loves Large Cap Biotech: 4 Top Stocks to Buy Now

Merrill Lynch recently highlighted sectors it considers a good opportunity now that are likely to outperform in the near term,…

Chris Lange | Sep 26, 2018 at 11:20 AM EDT

Verastem’s Copiktra Breaks Into China With New Licensing Deal

Verastem shares saw a handy gain on Wednesday after the company set an exclusive licensing agreement to develop and commercialize…

Chris Lange | Sep 26, 2018 at 8:50 AM EDT

Short Sellers Grow More Selective on Major Pharma Stocks

The September 14 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | Sep 26, 2018 at 8:15 AM EDT

Major Biotechs Have Short Sellers on the Run

The September 14 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Sep 24, 2018 at 12:50 PM EDT

Akcea and Ionis Pharma Win Big in Midstage Cardiovascular Disease Study

Akcea and Ionis Pharmaceuticals shares made a solid gain on Monday after the companies announced positive top-line data for a…

1 … 118 119 120 121 122 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Why Arrowhead Pharma’s New Agreement Is a Big Deal

Clovis Wins Big With FDA Update

Pfizer Announces Big Changes at the Top

Why Akorn Shares Were Halved

Major Biopharma Catalysts on October’s FDA Calendar

Equillium Prepares for IPO

Why Aldeyra Could Have Another 100% Upside, or More

US DEA Updates Schedule of Cannabidiol for GW Pharmaceuticals

Protagonist Therapeutics Wins FDA Fast Track

Why Geron Is Getting Crushed

Merrill Lynch Loves Large Cap Biotech: 4 Top Stocks to Buy Now

Verastem’s Copiktra Breaks Into China With New Licensing Deal

Short Sellers Grow More Selective on Major Pharma Stocks

Major Biotechs Have Short Sellers on the Run

Akcea and Ionis Pharma Win Big in Midstage Cardiovascular Disease Study

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

He Worked 20 Years for the Railroad, Then 20 Years Off It. His Social Security Benefit Cut His Railroad Tier I Dollar for Dollar.

‘Your Knowledge of Money and How It Works Is Nil’: Suze Orman to 62-Year-Old Who Nearly Locked His Wife Into $605 a Month

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

He Worked 20 Years for the Railroad, Then 20 Years Off It. His Social Security Benefit Cut His Railroad Tier I Dollar for Dollar.

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

He Worked 20 Years for the Railroad, Then 20 Years Off It. His Social Security Benefit Cut His Railroad Tier I Dollar for Dollar.

Health and Healthcare Articles

All Health and Healthcare Articles

Why Arrowhead Pharma’s New Agreement Is a Big Deal

Clovis Wins Big With FDA Update

Pfizer Announces Big Changes at the Top

Why Akorn Shares Were Halved

Major Biopharma Catalysts on October’s FDA Calendar

Equillium Prepares for IPO

Why Aldeyra Could Have Another 100% Upside, or More

US DEA Updates Schedule of Cannabidiol for GW Pharmaceuticals

Protagonist Therapeutics Wins FDA Fast Track

Why Geron Is Getting Crushed

Merrill Lynch Loves Large Cap Biotech: 4 Top Stocks to Buy Now

Verastem’s Copiktra Breaks Into China With New Licensing Deal

Short Sellers Grow More Selective on Major Pharma Stocks

Major Biotechs Have Short Sellers on the Run

Akcea and Ionis Pharma Win Big in Midstage Cardiovascular Disease Study

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

He Worked 20 Years for the Railroad, Then 20 Years Off It. His Social Security Benefit Cut His Railroad Tier I Dollar for Dollar.

‘Your Knowledge of Money and How It Works Is Nil’: Suze Orman to 62-Year-Old Who Nearly Locked His Wife Into $605 a Month

Featured Reads

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

He Worked 20 Years for the Railroad, Then 20 Years Off It. His Social Security Benefit Cut His Railroad Tier I Dollar for Dollar.